Two Pharma Stocks Enjoying Good Health
A stock I've written about numerous times here is Alexion Pharmaceuticals (ALXN). I have no sentimental attachment to it, nor do I particularly care what the "story" is. You could say that I'm not returning to the stock now, but that it's returning to me -- in the form of showing up again and again on my top-performing large-cap scans.
Alexion, which makes treatments for autoimmune disorders, transplant rejection conditions, cancer and various other ailments, is set to report its third quarter on Oct. 18 before the open. Wall Street has pegged earnings at $0.47 per share, up 27% from the year-earlier quarter....401 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.